Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study)

Abstract Background Prostate-specific membrane antigen (PSMA) has been shown to be overexpressed in the neo-vasculature of renal cancers. However, studies investigating the pattern of PSMA expression in primary RCC and RCC metastases according to metastatic sites are rare. 44 frozen samples of RCC,...

Full description

Saved in:
Bibliographic Details
Main Authors: Salma Binzaqr, David Kryza, Anne-Laure Giraudet, Jean Christophe Bernhard, Marine Gross-Goupil, Mokrane Yacoub, Gaelle Margue, Elif Hindié, Clément Morgat
Format: Article
Language:English
Published: SpringerOpen 2025-04-01
Series:EJNMMI Research
Subjects:
Online Access:https://doi.org/10.1186/s13550-025-01232-8
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849737236649607168
author Salma Binzaqr
David Kryza
Anne-Laure Giraudet
Jean Christophe Bernhard
Marine Gross-Goupil
Mokrane Yacoub
Gaelle Margue
Elif Hindié
Clément Morgat
author_facet Salma Binzaqr
David Kryza
Anne-Laure Giraudet
Jean Christophe Bernhard
Marine Gross-Goupil
Mokrane Yacoub
Gaelle Margue
Elif Hindié
Clément Morgat
author_sort Salma Binzaqr
collection DOAJ
description Abstract Background Prostate-specific membrane antigen (PSMA) has been shown to be overexpressed in the neo-vasculature of renal cancers. However, studies investigating the pattern of PSMA expression in primary RCC and RCC metastases according to metastatic sites are rare. 44 frozen samples of RCC, 19 primaries (9 clear cell (cc) RCC, 7 papillary (pap) RCC, and 3 chromophobe (ch) RCC) and 25 (24 samples have ccRCC histology and one is unclassified) unpaired metastases (8 from adrenals, 8 from bones, 2 from lungs, 2 from liver and 5 others (1 lymph node, 1 pancreas, 1 brain, 1 gallbladder and 1 muscle)), were available from the UroCCR project (NCT03293563). PSMA expression was assessed by autoradiography using [177Lu]Lu-PSMA-617 as binding agent and the specific binding (total binding—non-specific binding) was calculated and expressed as a percentage of total binding. A patient suffering from metastatic ccRCC was also administered [68Ga]Ga-PSMA-11 to evaluate PSMA expression. Results The mean specific binding was 28.9 ± 40.4% for primary renal cancer and 65.0 ± 38.9% for metastasis. Regarding histology, high PSMA expression was depicted in 33.3% of ccRCC, 33.3% of chRCC and 57.1% of papRCC. PSMA was more frequently expressed in primary samples of papRCC histology with renal capsule invasion (p = 0.0286). A higher PSMA-specific binding and a higher number of samples with high PSMA-expression were depicted in metastatic samples. Bone metastasis showed lower binding than other metastatic sites combined (p = 0.0005). The patient suffering from metastatic ccRCC showed high [68Ga]Ga-PSMA-11 uptake on known distant metastases and additional site uncovered. Conclusion PSMA showed high expression in metastases of ccRCC. Clinical trial registration NCT, NCT03293563, prospectively registered September 20, 2017, http://www.clinicaltrials.gov .
format Article
id doaj-art-2ed0d607bc874f28976a6b76e9c267e6
institution DOAJ
issn 2191-219X
language English
publishDate 2025-04-01
publisher SpringerOpen
record_format Article
series EJNMMI Research
spelling doaj-art-2ed0d607bc874f28976a6b76e9c267e62025-08-20T03:06:58ZengSpringerOpenEJNMMI Research2191-219X2025-04-011511910.1186/s13550-025-01232-8Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study)Salma Binzaqr0David Kryza1Anne-Laure Giraudet2Jean Christophe Bernhard3Marine Gross-Goupil4Mokrane Yacoub5Gaelle Margue6Elif Hindié7Clément Morgat8Department of Nuclear Medicine, University Hospital of BordeauxUniv. Lyon - Université Claude Bernard Lyon 1, LAGEPP UMR 5007 CNRSUniv. Lyon - Université Claude Bernard Lyon 1, LAGEPP UMR 5007 CNRSDepartment of Urology, University Hospital of BordeauxDepartment of Urology, University Hospital of BordeauxDepartment of Pathology, University Hospital of BordeauxDepartment of Urology, University Hospital of BordeauxDepartment of Nuclear Medicine, University Hospital of BordeauxDepartment of Nuclear Medicine, University Hospital of BordeauxAbstract Background Prostate-specific membrane antigen (PSMA) has been shown to be overexpressed in the neo-vasculature of renal cancers. However, studies investigating the pattern of PSMA expression in primary RCC and RCC metastases according to metastatic sites are rare. 44 frozen samples of RCC, 19 primaries (9 clear cell (cc) RCC, 7 papillary (pap) RCC, and 3 chromophobe (ch) RCC) and 25 (24 samples have ccRCC histology and one is unclassified) unpaired metastases (8 from adrenals, 8 from bones, 2 from lungs, 2 from liver and 5 others (1 lymph node, 1 pancreas, 1 brain, 1 gallbladder and 1 muscle)), were available from the UroCCR project (NCT03293563). PSMA expression was assessed by autoradiography using [177Lu]Lu-PSMA-617 as binding agent and the specific binding (total binding—non-specific binding) was calculated and expressed as a percentage of total binding. A patient suffering from metastatic ccRCC was also administered [68Ga]Ga-PSMA-11 to evaluate PSMA expression. Results The mean specific binding was 28.9 ± 40.4% for primary renal cancer and 65.0 ± 38.9% for metastasis. Regarding histology, high PSMA expression was depicted in 33.3% of ccRCC, 33.3% of chRCC and 57.1% of papRCC. PSMA was more frequently expressed in primary samples of papRCC histology with renal capsule invasion (p = 0.0286). A higher PSMA-specific binding and a higher number of samples with high PSMA-expression were depicted in metastatic samples. Bone metastasis showed lower binding than other metastatic sites combined (p = 0.0005). The patient suffering from metastatic ccRCC showed high [68Ga]Ga-PSMA-11 uptake on known distant metastases and additional site uncovered. Conclusion PSMA showed high expression in metastases of ccRCC. Clinical trial registration NCT, NCT03293563, prospectively registered September 20, 2017, http://www.clinicaltrials.gov .https://doi.org/10.1186/s13550-025-01232-8Primary RCCPSMAMetastatic RCCClear cell RCCKidney cancer
spellingShingle Salma Binzaqr
David Kryza
Anne-Laure Giraudet
Jean Christophe Bernhard
Marine Gross-Goupil
Mokrane Yacoub
Gaelle Margue
Elif Hindié
Clément Morgat
Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study)
EJNMMI Research
Primary RCC
PSMA
Metastatic RCC
Clear cell RCC
Kidney cancer
title Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study)
title_full Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study)
title_fullStr Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study)
title_full_unstemmed Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study)
title_short Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study)
title_sort prostate specific membrane antigen psma expression in primary and metastatic renal cell cancer uroccr 65 study
topic Primary RCC
PSMA
Metastatic RCC
Clear cell RCC
Kidney cancer
url https://doi.org/10.1186/s13550-025-01232-8
work_keys_str_mv AT salmabinzaqr prostatespecificmembraneantigenpsmaexpressioninprimaryandmetastaticrenalcellcanceruroccr65study
AT davidkryza prostatespecificmembraneantigenpsmaexpressioninprimaryandmetastaticrenalcellcanceruroccr65study
AT annelauregiraudet prostatespecificmembraneantigenpsmaexpressioninprimaryandmetastaticrenalcellcanceruroccr65study
AT jeanchristophebernhard prostatespecificmembraneantigenpsmaexpressioninprimaryandmetastaticrenalcellcanceruroccr65study
AT marinegrossgoupil prostatespecificmembraneantigenpsmaexpressioninprimaryandmetastaticrenalcellcanceruroccr65study
AT mokraneyacoub prostatespecificmembraneantigenpsmaexpressioninprimaryandmetastaticrenalcellcanceruroccr65study
AT gaellemargue prostatespecificmembraneantigenpsmaexpressioninprimaryandmetastaticrenalcellcanceruroccr65study
AT elifhindie prostatespecificmembraneantigenpsmaexpressioninprimaryandmetastaticrenalcellcanceruroccr65study
AT clementmorgat prostatespecificmembraneantigenpsmaexpressioninprimaryandmetastaticrenalcellcanceruroccr65study